FAM
PTGX icon

Fulcrum Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Fulcrum Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.59K Buy
+46
New +$4.8K ﹤0.01% 747

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fulcrum Asset Management's PTGX Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 46 shares worth $5.59K. The stake represents ﹤0.01% of the portfolio and ranks #747 among its holdings.

343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Fulcrum Asset Management held 46 shares of Protagonist Therapeutics worth $5.59K as of Q2 2026.
  • Protagonist Therapeutics was a new Fulcrum Asset Management position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #747 holding.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.